Toward a Shared Vision for Cancer Genomic Data
By Robert L. Grossman, Allison P. Heath, V. Ferretti, H. Varmus, D. Lowy, Warren A. Kibbe, Louis Staudt. New England Journal of Medicine, 2016
1,463 citations recorded by the source corpus.
The Genomic Data Commons will initially house raw genomic data and diagnostic, histologic, and clinical outcome data from National Cancer Institute–funded projects. A harmonization process will align sequencing data to the genome and identify mutations and alterations.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/b2ab0b2201554f7d744dde7a78dbc7b30d706252
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- Multimodal data fusion for cancer biomarker discovery with deep learning (2023, background): “Large consortia such as The Cancer Genome Atlas (TCGA) and Genomic Data Commons have gathered and standardized large datasets, accumulating petabytes of genomic, expression and proteomics data 37,49,50 .”
- Diffusion models in medical imaging: A comprehensive survey (2022, methodology): “Experiments on the Cancer Genome Atlas (TCGA) dataset [126] exhibit the superiority of the proposed method compared to GAN-based approaches [127].”
- The National Sleep Research Resource: towards a sleep data commons (2018, background): “We believe that the Data Commons vision is best achieved by in-stantiating it through disease-or domain-specific efforts, such as the NCI Genomic Data Commons (GDC 47,48 ).”
- AACR Project GENIE: Powering Precision Medicine through an International Consortium (2017, background): “Broad-based sharing of genomic and clinical data is therefore critical to realize the full potential of precision oncology (1), particularly as the scientific community evaluates the overall impact of genomic profiling on patient outcome and on clinical trial enrollment (2–5), and as the clinical co”
- CCRK is a novel signalling hub exploitable in cancer immunotherapy (2018, neutral): “According to the gene profile data in the NCI Genomic Data Commons (GDC) (Grossman et al., 2016), CCRK is susceptible to genetic mutations spanning almost the entire coding region, which cause early truncation, missense and frameshift mutations (Fig.”